

Table 2. Microbial causes of infections according to site, and type of host, and recommended empiric antimicrobial therapy.

| Newborn | | |
|--|------------------------------------|---|
| Site of Infections | Organisms | Antimicrobials |
| Sepsis, Meningitis | Streptococcus agalactiae (group B) | Ampicillin |
| | Escherichia coli | cefotaxime ^{@&} |
| | Other Gram-negative rods | cefotaxime ^{@&} |
| | Listeria monocytogenes | Ampicillin +/- gentamicin |
| | Herpes simplex virus | Acyclovir |
| | Enterovirus | None |
| [@] For Gram-negative rod Sepsis, gentamicin is appropriate, but for meningitis, cefotaxime should be used. | | |
| ^{&} Because extended-spectrum beta-lactamases are being noted in E. coli, if Gram-negative rods are seen on Gram stain or are cultured, meropenem should be used instead of cefotaxime, until susceptibilities are known. | | |
| Empiric Therapy: Sepsis - Ampicillin + (gentamicin or cefotaxime) +/- acyclovir | | |
| Empiric therapy: Meningitis - Ampicillin + cefotaxime + acyclovir | | |
| Pneumonia | Streptococcus agalactiae | See above for sepsis |
| | Escherichia coli | See above for sepsis |
| | Respiratory viruses | None currently |
| | Chlamydia trachomatis | Azithromycin or erythromycin |
| | Herpes simplex virus | Acyclovir |
| Empiric therapy: Pneumonia - Ampicillin + (gentamicin or cefotaxime) +/- macrolide | | |
| URINARY TRACT INFECTION | Escherichia coli | See above for sepsis |
| SKELETAL (bone, joint) | Streptococcus agalactiae | Ampicillin |
| | Staphylococcus aureus | Vancomycin or nafcillin* |
| | Gram-negative rods | See above for sepsis |
| Empiric therapy: Vancomycin or nafcillin* + cefotaxime | | |
| [*] See comment in Table 1 about Staphylococcus aureus resistance to methicillin | | |
| NECROTIZING ENTEROCOLITIS | Gram-negative rods, anaerobes | Cefotaxime or gentamicin) + metronidazole or meropenem alone [#] |
| [#] Meropenem is very active against most Gram-negative rods and anaerobes, so it can be used alone. | | |
| OMPHALITIS | Staphylococcus aureus | Vancomycin or nafcillin* |
| | Gram-negative rods | Gentamicin |
| | Anaerobes | Metronidazole |
| Empiric therapy should be active against all these pathogens | | |
| CONJUNCTIVITIS | Neisseria gonorrhoeae | Ceftriaxone |
| | Chlamydia trachomatis | Azithromycin or erythromycin |
| | Staphylococcus aureus | Topical gentamicin or polymyxin |
| NORMAL INFANT AND CHILD | | |

| | | |
|--|--|---|
| Sepsis (bacteremia) | Streptococcus pneumoniae | Penicillin, ampicillin, ceftriaxone or cefotaxime |
| | Neisseria meningitidis | Penicillin, ceftriaxone |
| | Haemophilus influenzae# | Cefotaxime or ceftriaxone |
| | Staphylococcus aureus | Vancomycin or nafcillin* |
| | Salmonella spp. | Ceftriaxone or cefotaxime |
| #H. influenzae type b (HIB) was a very common cause of bacteremia, meningitis, skeletal infections, epiglottitis and facial cellulitis prior to the widespread use of the (HIB) vaccine in the early 1990s. It is now very rare in the USA and other countries where the vaccine is used. | | |
| Empiric therapy for sepsis: Ceftriaxone and cefotaxime are active against most causes of bacteremia in previously normal children. However, if there are focal symptoms or signs, such as limp or abscesses, Staphylococcus aureus infection should be strongly suspected, and vancomycin should be added. | | |
| Toxic shock syndrome | Staphylococcus aureus, Streptococcus pyogenes | Vancomycin (or nafcillin*) + clindamycin ^{&} +/- intravenous gamma globulin (IVIG) |
| &The reason for adding clindamycin is for its ability to inhibit toxin production | | |
| NERVOUS SYSTEM INFECTIONS | | |
| Meningitis | Streptococcus pneumoniae ^S | Ceftriaxone or cefotaxime, vancomycin |
| | Haemophilus influenzae type b [#] | Cefotaxime or ceftriaxone |
| | Neisseria meningitidis | Penicillin, ceftriaxone |
| §Empiric therapy for meningitis: Because strains of Streptococcus pneumoniae resistant to penicillin, cefotaxime, and ceftriaxone are prevalent worldwide, vancomycin should be used IN ADDITION TO ceftriaxone or cefotaxime, until identification of an organism and antimicrobial susceptibilities have been determined. | | |
| Chronic meningitis | Tuberculous | Isoniazid + rifampin + pyrazinamide + ethionamide; consult infectious diseases specialist |
| | Cryptococcal | Amphotericin B + flucytosine; consult infectious diseases specialist |
| Other infections of the brain: | | |
| Encephalitis: in most cases an etiology is never identified | Enteroviruses | None |
| | Arthropod-borne viruses | None |
| | Herpes simplex virus | Acyclovir |
| | Rickettsiae | Doxycycline |
| | Bartonella henselae | Doxycycline |
| | Borrelia burgdorferi (Lyme disease) | Ceftriaxone |
| Empiric therapy for encephalitis: ceftriaxone + acyclovir + doxycycline | | |
| Ventriculo-peritoneal shunt | Staphylococci, Gram-negative rods, diphtheroids, Bacillus spp. | Vancomycin + ceftriaxone |
| Brain Abscess | Streptococci, anaerobes, staphylococci, Gram-negative rods | (Vancomycin + meropenem) OR (vancomycin + ceftriaxone + metronidazole) |
| Poliomyelitis | Polio viruses | No therapy |
| | Tetanus | Supportive, tetanus immune globulin + (metronidazole or penicillin) |
| | Botulism | Supportive, botulinum immune globulin: Infant botulism - Baby BIG – call 510-231-7600; foodborne and |

wound botulism: bivalent equine antitoxin – call CDC 770-488-7100; also call state laboratory

UPPER RESPIRATORY TRACT:

Pharyngitis:

Respiratory viruses: Adeno-, parainfluenza-, respiratory syncytial-, rhino- Streptococcus pyogenes (Group A) Penicillin, ampicillin, clindamycin, macrolide

Diphtheria Corynebacterium diphtheriae Diphtheria antitoxin + (erythromycin or penicillin)

Acute Otitis Media Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis Amoxicillin, amoxicillin/clavulanate, cefdinir, cefpodoxime

Mastoiditis Streptococcus pneumoniae, Streptococcus pyogenes, Staphylococcus aureus (ceftriaxone or cefotaxime) + (clindamycin or vancomycin*)

Sinusitis Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis Amoxicillin, amoxicillin/clavulanate, cefdinir, cefpodoxime

Retropharyngeal Abscess Staphylococcus aureus, anaerobes, oral Gram-negative rods ((ceftriaxone or cefotaxime) + clindamycin) or ampicillin/sulbactam*

*ampicillin/sulbactam is suitable only if Staphylococcus aureus resistant to methicillin is excluded or unlikely.

MIDDLE RESPIRATORY TRACT:

Epiglottitis Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus pyogenes Ceftriaxone or cefotaxime

Acute Laryngotracheobronchitis Respiratory viruses (parainfluenza-, respiratory syncytial-, adeno-, influenza viruses) No antimicrobial therapy

Bacterial tracheitis Staphylococcus aureus, Streptococcus pyogenes Vancomycin*

LOWER RESPIRATORY TRACT:

Bronchiolitis Respiratory viruses (respiratory syncytial-, parainfluenza virus) No antimicrobial therapy

Pertussis Macrolide

Pneumonia Respiratory viruses (respiratory syncytial virus, parainfluenza virus, adenovirus, metapneumovirus) None

Influenza viruses§ Osteltamavir, zanamivir, rimantadine, amantadine

§ Check current recommendations, from sources such as the CDC (www.cdc.gov)

Streptococcus pneumoniae ceftriaxone

Staphylococcus aureus Vancomycin or nafcillin*, linezolid (daptomycin should NOT be used for patients with pneumonia) clindamycin for less severe cases

Mycoplasma pneumoniae Macrolide, doxycycline^, fluoroquinolone

Chlamydia pneumoniae Macrolide, doxycycline^

^Doxycycline should not be used in this situation in children younger than 8 years

Empiric therapy: infant: (ceftriaxone or cefotaxime) +/- treatment active against Staphylococcus aureus

Older child: (ceftriaxone or cefotaxime) + macrolide +/- treatment active against Staphylococcus aureus

| | | |
|---|--|---|
| Empyema | Streptococcus aureus, Streptococcus pneumoniae | (ceftriaxone or cefotaxime) + vancomycin* |
| Nosocomial and Ventilator-associated pneumonia | | See Hospital-acquired infections below |
| SKIN and SOFT TISSUE INFECTIONS | | |
| Cellulitis | Staphylococcus aureus, Streptococcus pyogenes | Clindamycin or nafcillin*, (vancomycin for severe infections) |
| Fasciitis, Myositis | Staphylococcus aureus, Streptococcus pyogenes | Vancomycin or nafcillin* +/- clindamycin (see toxic shock syndrome above) if perineal, consider Gram-negative rod and anaerobes, and add piperacillin/tazobactam or meropenem. |
| Wound# | Staphylococcus aureus, Streptococcus pyogenes | See skin infections above – if contaminated or perineal – consider Gram-negative rods and anaerobes and add piperacillin/tazobactam or meropenem |
| Gas gangrene | Clostridium perfringens, other histotoxic clostridia | Meropenem + surgery |
| Burn# | Staphylococcus aureus, Pseudomonas aeruginosa | Vancomycin or clindamycin or nafcillin* + (ceftazidime or piperacillin/tazobactam or aminoglycoside) |
| Ecthyma gangrenosum | Pseudomonas aeruginosa, other Gram-negative rods, Aspergillus spp., Zygomycetes | Ceftazidime or piperacillin/tazobactam% |
| %An urgent biopsy should be performed | | |
| Bites:# | | |
| Human++ | Staphylococcus aureus, Streptococcus pyogenes, oral Gram-negative rods, anaerobe | Ampicillin/sulbactam or amoxicillin/clavulanate + (clindamycin or vancomycin*) |
| Ampicillin/sulbactam and amoxicillin/clavulanate are active against methicillin-susceptible Staphylococcus aureus | | |
| Dog, cat, other mammal | Staphylococcus aureus, streptococci, Pasteurella spp., Neisseria spp., Capnocytophaga spp. | Ampicillin, sulbactam or amoxicillin/clavulanate + (clindamycin or vancomycin*) |
| Shark | Vibrios | Ciprofloxacin, cefotaxime, doxycycline, aminoglycosides |
| Alligator/crocodile | Aeromonas hydrophila, Pseudomonas spp., other Gram-negative rods, anaerobes | Piperacillin/tazobactam |
| Rat | Streptobacillus moniliformis | Penicillin |
| Monkey (old World) | Herpes simiae | Acyclovir |
| Snake | Staphylococcus aureus, E. coli | Ampicillin/sulbactam |
| In cases of animal bites, the potential for rabies exposure should be evaluated, and, if indicated, post-exposure management with rabies immune globulin and rabies vaccine given. | | |
| ++ Risk for transmission of HIV, hepatitis B and hepatitis C should be determined | | |
| URINARY TRACT INFECTIONS | | |
| | E. coli, Klebsiella, other Gram-negative rods | Cefotaxime or ceftriaxone or aminoglycoside |
| | Enterococcus | Ampicillin; nitrofurantoin, only for lower tract infection |
| ABDOMINAL INFECTIONS | | |
| Perforated bowel | Gram-negative rods, anaerobes | Carbapenem, piperacillin/tazobactam, ticarcillin/clavulanic acid OR ceftriaxone, cefotaxime, ceftazidime, ciprofloxacin or levofloxacin each with metronidazole OR gentamicin + |

| | | |
|--------------------------------------|---|---|
| Cholecystitis | Gram-negative rods, anaerobes | metronidazole Carbapenem, piperacillin/tazobactam OR cefepime, ciprofloxacin or levofloxacin, each with metronidazole |
| Cholangitis | Gram-negative rods, anaerobes | Carbapenem, piperacillin/tazobactam OR cefepime, ciprofloxacin or levofloxacin, each with metronidazole |
| Liver abscess: bacterial | Streptococcus, Gram-negative rods, anaerobes | (ceftriaxone + metronidazole) or carbapenem |
| Liver abscess: amebic | Entamoeba histolytica | Metronidazole or tinidazole |
| Primary peritonitis | Streptococcus pneumoniae, Gram-negative rods | Ceftriaxone |
| GASTRO-INTESTINAL INFECTIONS: | | |
| Gastroenteritis: | | |
| Viral: | (rotavirus, norovirus, enteric adenovirus) | Supportive therapy only |
| Bacterial: | Salmonella | Supportive therapy only unless bacteremia is suspected, or in infants < 3 months or patients with sickle cell disease: ceftriaxone |
| | Shigella | Ceftriaxone (Although this organism can be susceptible to ampicillin and trimethoprim/sulfamethoxazole resistance is frequent.) |
| | Campylobacter | Azithromycin, ciprofloxacin |
| | Yersinia enterocolitica | If suspected bacteremia: gentamicin, ceftriaxone, trimethoprim/sulfamethoxazole |
| | Clostridium difficile | Metronidazole (orally or parenterally) or vancomycin (only orally) |
| | Cholera (Vibrio Cholerae) | Doxycycline, ciprofloxacin, azithromycin, trimethoprim/sulfamethoxazole |
| | E. coli: traveler's diarrhea | Ciprofloxacin, azithromycin |
| Protozoal: | Giardia intestinalis | Metronidazole or tinidazole |
| | Entamoeba histolytica | Metronidazole or tinidazole |
| | Cryptosporidium hominis | Nitazoxanide |
| | Cyclospora cayetanensis | Trimethoprim/sulfamethoxazole |
| | Isospora belli | Trimethoprim/sulfamethoxazole |
| Typhoid fever | (Salmonella typhi and S. paratyphi infection) | Ceftriaxone (although this organism may susceptible to ampicillin, trimethoprim/sulfamethoxazole, chloramphenicol and ciprofloxacin, resistance is fairly common) |
| Esophagitis | | |
| | Herpes simplex virus | Acyclovir |
| | Candida | Fluconazole |
| | Cytomegalovirus | Gancyclovir |
| GENITAL INFECTIONS: | | |
| Pelvic inflammatory disease | Neisseria gonorrhoeae, Chlamydia trachomatis, Gram-negative rods, | (Cefoxitin or cefotetan) + doxycycline |

| | | |
|---|---|---|
| | anaerobes | |
| CARDIOVASCULAR INFECTIONS | | |
| Infective endocarditis (see Baddour LM et al): | | |
| Native heart | Staphylococcus aureus, streptococci, enterococci, "HACEK" group of Gram-negative rods^ | Vancomycin + gentamicin* +/- ceftriaxone |
| ^Haemophilus aphrophilus (now called Aggregatibacter aphrophilus), Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella kingae) | | |
| *low dose gentamicin, for synergistic activity | | |
| Nosocomial | | |
| | Complicating vascular catheter infection: staphylococci, enterococci, Candida spp. | |
| | Post-operative and prosthetic valve/material: coagulase-negative staphylococci, Staphylococcus aureus, Corynebacteria, Gram-negative rods, and fungi, especially Candida spp. | Vancomycin + gentamicin + rifampin + cefepime |
| | Associated with intravenous drug abuse: Staphylococci aureus, Gram-negative rods | Vancomycin + gentamicin + ceftazidime |
| | Fungal | Amphotericin B |
| Pericarditis | Staphylococcus aureus, Haemophilus influenzae, Streptococcus pneumoniae, Neisseria meningitidis | Vancomycin + ceftriaxone |
| Myocarditis | Usually virus | |
| Septic jugular thrombophlebitis (Lemierre's syndrome) | Fusobacterium necrophorum | Metronidazole |
| EYE: | | |
| Conjunctivitis | Adenovirus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis | Topical polymyxin or gentamicin |
| Other ocular diseases including keratitis, uveitis, endophthalmitis, retinitis | | Consult ophthalmologist |
| Periorbital and orbital cellulitis | Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae | Ceftriaxone + (clindamycin or vancomycin)* |
| ABNORMAL HOST: | | |
| HIV/AIDS: | | |
| Pneumonia | Same causes as in non HIV-infected children of same age + Pneumocystis jirovecii, cytomegalovirus, Mycobacterium tuberculosis | Ceftriaxone + trimethoprim/sulfamethoxazole |
| Bacteremia | Same causes as in non HIV-infected children of same age + Staphylococcus aureus, Gram-negative rods, Listeria monocytogenes | Ceftriaxone + ampicillin +/- vancomycin |

| | | |
|---|--|---|
| Sickle Cell Disease: | | |
| Bacteremia | Streptococcus pneumoniae | Ceftriaxone or cefotaxime |
| Acute Chest Syndrome | Streptococcus pneumoniae, Mycoplasma pneumoniae | Ceftriaxone + macrolide |
| Osteomyelitis | Staphylococcus aureus, Salmonella – try to obtain organism | (clindamycin or vancomycin*) + ceftriaxone |
| Primary immunodeficiencies: | | |
| Chronic granulomatous disease | Staphylococcus aureus, Aspergillus, Serratia marcescens, Burkholderia cepacia | |
| Immunoglobulin deficiency | Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Pseudomonas spp. | |
| Severe combined immunodeficiency | Wide range of viral, bacterial, and fungal organisms, including cytomegalovirus, herpes simplex virus, Streptococcus pneumoniae, Haemophilus influenzae, Gram-negative rods, including Salmonella spp., Listeria monocytogenes, Mycobacteria, and Pneumocystis jirovecii | |
| Complement deficiency | | |
| Terminal complement factors | Neisseria meningitidis | |
| Chemotherapy-induced neutropenia ("fever and neutropenia), usually hospital-acquired | Staphylococci, viridans streptococci, Gram-negative rods, including Pseudomonas aeruginosa, fungi | (piperacillin/tazobactam or cefepime or ceftazidime or meropenem) + aminoglycoside + vancomycin* - if persistently febrile after 4 days, add antifungal agent, such as voriconazole |
| Transplant: See Table 1 | | |
| Bone Marrow - These should be considered according to the following categories: donor-derived, recipient-derived and reactivated, nosocomial, and community-acquired, and in the time periods after transplantation: < 1 month, 1 month - 100 days, and > 100 days. | | |
| In addition to a wide range of bacteria associated with neutropenia (see above) these patients are at risk for infection with the following organisms: | | |
| | Adenovirus | Consider cidofovir |
| | Cytomegalovirus | Gancyclovir, foscarnet |
| | Herpes simplex virus | Acyclovir |
| | Human herpes virus 6 | Consider gancyclovir, foscarnet |
| Fungi | Candida | Fluconazole, echinocandins, amphotericin B |
| | Aspergillus | Voriconazole, amphotericin B |
| | Zygomycetes | Posaconazole, amphotericin B |
| | Pneumocystis jirovecii | Trimethoprim/sulfamethoxazole, clindamycin + primaquine%, atovaquone, pentamidine |
| %glucose-6-phosphate dehydrogenase deficiency should be excluded before primaquine is used. | | |
| Solid organ (see Fishman JA) – These should be considered in the following categories: donor-derived, recipient-derived and reactivated, nosocomial, and community - acquired, and in the following time periods after transplantation: < 1 month, 1-6 months, and > 6 months. | | |
| Cystic fibrosis: pneumonia | | |
| | Staphylococcus aureus | Clindamycin or vancomycin* |
| | Pseudomonas aeruginosa | Piperacillin, cefazidime, tobramycin, amikacin, meropenem, ciprofloxacin |

| | | |
|---|--|--|
| | Burkholderia cepacia | Meropenem, trimethoprim/sulfamethoxazole, ticarcillin/clavulante, minocycline |
| Iron overload (hemochromatosis, repeated blood transfusions): | | |
| | Yersina enterocolitica, some other Gram-negative rod infections, zygomycetes | Ceftriaxone |
| | Vibrio vulnificus (specific exposure) | ((ceftazidime or cefotaxime) + doxycycline) or ciprofloxacin |
| Nephrotic syndrome: bacteremia, primary peritonitis | Streptococcus pneumoniae, Gram-negative rods | Ceftriaxone |
| Liver disease with ascites: bacteremia, primary peritonitis | | |
| | Streptococcus pneumoniae, Gram-negative rods | Ceftriaxone |
| | Vibrio vulnificus (specific exposure) | ((ceftazidime or cefotaxime) + doxycycline) or ciprofloxacin |
| SPECIFIC INFECTION SYNDROMES | | |
| Anthrax | | Consult infectious diseases specialist |
| Cat scratch disease | | Azithromycin, trimethoprim/sulfamethoxazole |
| Hantavirus pulmonary syndrome | | Supportive |
| Infectious mononucleosis, normal host: | | |
| | Epstein-Barr virus | No treatment |
| | Cytomegalovirus | No treatment |
| | Toxoplasmosis | No treatment |
| | HIV | Consult specialist |
| Influenza (see pneumonia) | | |
| Leptospirosis | | Doxycycline, penicillin, macrolide |
| Malaria | | |
| Falciparum: | Severe (>5% parasitemia, evidence of organ dysfunction) | Quinidine intravenously or artesunate intravenously (contact CDC malaria hotline: 770-488-7788, after hours 770-488-7100, ask for Dr on call for malaria.) See dosages in Table 3. |
| | Not severe, acquired in area of chloroquine resistance | Quinine (orally) or atovaquone/proguanil (orally) |
| | Not severe, acquired in area of chloroquine susceptibility | Chloroquine (orally) |
| Non-falciparum | | Chloroquine (orally) |
| Unknown species | | As for falciparum |
| Rickettsial and Ehrlichial Infection (Rocky Mountain spotted fever and Ehrlichiosis) | | Doxycycline (irrespective of age) |
| Tuberculosis | | Consult infectious diseases specialist |
| Varicella | | Acyclovir |
| Viral hemorrhagic fever | | Contact CDC (770-488-7100) |

HOSPITAL –ACQUIRED INFECTIONS

Patients who develop infection while in the hospital are at risk for infection caused by organisms resistant to many antimicrobial agents because such organisms are often endemic in hospitals (due to selective pressure from widespread usage) and the fact that patient might have already received antimicrobial therapy. One should assume that an infection developing in a patient who has recently received a particular agent is resistant to that agent. In choosing an antimicrobial agent, one should be guided by the local (within the particular unit) epidemiology of organisms and their antimicrobial susceptibility patterns.

| | |
|--|--|
| Ventilator-associated pneumonia | Gram-negative rods (<i>Pseudomonas aeruginosa</i> , Enterobacteriaceae) <i>Staphylococcus aureus</i> , <i>Candida</i> spp. |
| Vascular-catheter infections | <i>Staphylococci</i> , <i>Candida</i> spp., enterococcus, Gram-negative rods |
| Urinary tract infections | Gram-negative rods, enterococcus, <i>Candida</i> spp. |
| Surgical wound infections | <i>Staphylococcus aureus</i> , Gram-negative rods |

*In areas where methicillin-resistant *Staphylococcus aureus* (MRSA) is prevalent (most of USA) patients with severe infections presumed to be caused by this organism should be treated with vancomycin. If cultures demonstrate susceptibility to methicillin, then nafcillin, oxacillin or ceftazolin can be used. (see *Staphylococcus aureus* table 1)